Export House Status Holders are revered business leaders who have excelled in the realm of international trade Venus Remedies Limited, a noted name in the pharmaceutical industry, has received the prestigious "Three Star Export House" certificate from the Government of India. This certificate, given to
Obtaining market authorization for Bleomycin from MHRA is a momentous accomplishment for Venus Pharma GmbH. Venus Remedies holds a total of 15 Market Authorizations (MA) for Bleomycin products across the globe. Venus Remedies is thrilled to announce the achievement of market authorization in the United Kingdom
As the first pharmaceutical company in India to be honored with the REO certification from CII, Venus Remedies stands at the forefront of responsible and sustainable export practices. The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian
The $4.20-billion pharmaceutical market of the Philippines accounts for a significant market for Venus Remedies from the ASEAN region as the company moves a step closer towards emerging as the top oncology medicine supplier from India in Southeast Asia Venus Remedies’ oncology wing has
The Ecuador antibiotics market is majorly dependent on imports from India. Ecuador had imported antibiotics worth US $3.5 million in 2022. The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in
Oncology drugs constitute the largest proportion of the Serbian pharmaceutical market, where Venus Remedies has so far secured five marketing approvals, all in the oncology space The company is banking on the product registration from Serbia to pave the way for faster approvals for
The company expects this marketing approval to enable it to rapidly expand its operations not only in Saudi Arabia, the largest pharma market in GCC region, but other GCC and MENA countries as well The marketing authorisation from Saudi Arabia comes as an evident
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025 Venus Remedies is targeting the $237-million antibiotic market in GCC region, out of which 35 per cent accounts for
The company has consolidated its position in ASEAN, South America and Eastern Europe regions Venus Remedies has taken another decisive step towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region with the product registration from
The company has consolidated its position in GCC, ASEAN, Balkan and Caribbean regions with marketing approvals from Oman, Malaysia, Bosnia and Trinidad & Tobago for important chemotherapy drugs With this, the number of marketing approvals for its oncology products across 75 countries has gone
